A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

Exclusion Criteria

• •History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, biliary (including gallstones or previous cholecystectomy), endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
• •Have a history of malignant neoplasm (excepting definitively treated non melanoma skin cancer or carcinoma in situ of the uterine cervix, which may be enrolled at any time) within the last 5 years.
• •Past or intended use of over-the-counter or prescription medication including herbal medications within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing.
• •Participation in the clinical study would result in loss of blood or blood products in excess of 500 milliliter (mL) within 3 months.
• •Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
• •Current enrolment or past participation in another investigational clinical study in which an investigational intervention (e.g., drug, vaccine, invasive device) was administered within the last 30 days or 5.5 half-lives before signing of consent in any other clinical study involving an investigational study intervention or any other type of medical research.
• •Current enrolment or past participation in this clinical study.
• •Positive pre-study drug/alcohol screen, including tetrahydrocannabinol.
• •Positive Human immunodeficiency virus (HIV) antibody test.
• •Positive coronavirus (severe acute respiratory syndrome coronavirus 2 \[SARS-CoV-2\]) polymerase chain reaction test at check-in.
• •Presence of Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention.
• •Positive Hepatitis C virus (HCV) antibody test result at screening or within 3 months prior to starting study intervention.
• •Total bilirubin \>1.5x upper limit of normal (ULN), including participants with Gilbert's syndrome.
• •Regular alcohol consumption within 6 months prior to the clinical study defined as: For sites in United States of America (USA), an average weekly intake of 3 units for males or 1.5 units for females.
• •History of known drugs of abuse, including tetrahydrocannabinol, in last 5 years.
• •Sensitivity to heparin or heparin-induced thrombocytopenia.
• •Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the clinical study.
• •Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.), within past 30 days prior to signing the consent and during the study.
• •Any dietary restrictions that would prevent the participant from consuming the site menu/meals.